The Ubiquitin-Proteasome Pathway an Emerging Anticancer Strategy for Therapeutics: A Patent Analysis

Author(s): Chakresh K. Jain, Shivam Arora, Aparna Khanna, Money Gupta, Gulshan Wadhwa, Sanjeev K. Sharma.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 10 , Issue 2 , 2015

Become EABM
Become Reviewer


The degradation of intracellular proteins is targeted by ubiquitin via non-lysosomal proteolytic pathway in the cell system. These ubiquitin molecules have been found to be conserved from yeast to humans. Ubiquitin proteasome machinery utilises ATP and other mechanisms for degrading proteins of cytosol as well as nucleus. This process of ubiquitination is regulated by activating the E3 enzyme ligase, involved in phosphorylation. In humans, proteins which regulate the cell cycle are controlled by ubiquitin; therefore the ubiquitin-proteasome pathway can be targeted for novel anti-cancer strategies. Dysregulation of the components of the ubiquitin system has been linked to many diseases like cancer and inflammation. The primary triggering mechanism (apoptosis) of these diseases can also be induced when TNF-related apoptosis-inducing ligand (TRAIL) binds to its specific receptor DR4 and DR5. In this review, the emerging prospects and importance of ubiquitin proteasome pathway as an evolving anticancer strategy have been discussed. Current challenges in the field of drug discovery have also been discussed on the basis of recent patents on cancer diagnosis and therapeutics.

Keywords: Apoptosis, cancer, CDK, NF-KB alternative pathway, p27 (a cyclin dependent kinase), proteasome pathway, TRAIL pathway, ubiquitin, ubiquitin machinery.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [201 - 213]
Pages: 13
DOI: 10.2174/1574892810666150416111213
Price: $58

Article Metrics

PDF: 33
PRC: 1